运动对抵抗素水平的影响及与胰岛素抵抗改善的相关性

在简要概述抵抗素生物学的基础上,对近年国内外有关运动与抵抗素的研究文献进行了回顾。注意到无论运动对抵抗素水平是否有影响,但可提高胰岛素敏感性,至于运动改善IR是否通过降低抵抗水平这一机制实现尚难以确定,且研究较少。     

非线性模拟量检测的多点定标方法

嵌入式系统和集散控制系统中,待测模拟量一般都是非线性的。为实现非线性模拟量的精确、快速检测,提出了非线性模拟量的多点定标检测方法。分别给出了分段线性化和分段变频率两种定标方法的编程思路,可提高非线性模拟量检测的精度和局部分辨率。     

大断面强流变软岩硐室加固技术相似模拟试验研究

针对鹤煤九矿井下硐室出现浆皮开裂、底臌等类似现象,采用相似模拟的方法,以鹤煤九矿31采区避难硐室临近硐室群实际地质资料为基础,研究分析了给定应力环境下不同支护方式时硐室围岩的变形破坏情况、失稳过程。作者认为,随着顶部压力的逐渐改变,顶板裂隙逐渐增加,裂隙深度和宽度逐步增加,巷道出现离层、底鼓,进而呈现大面积破坏。该结果对区段巷道布置与加固方案优化有一定的参考价值。     

固液转化水溶剂模拟因子选择的探讨

察尔汗盐湖首采矿区固体钾资源的固液转化,模拟以Mg2+为主的水溶剂,并提出在固液转化中遇到问题的处理思路。     

小波函数的电路合成方法

针对国内对小波的研究主要集中在算法和应用方面,小波的电路实现方法研究还鲜见的现状,提出了一种小波函数的电路实现方法。小波函数使用反曲型母小波模拟,电路由双极型晶体管、可控放大器和线性无源电子元件等组成。根据小波分解的多分辨率近似特性,有限能量多变量函数能使用这个模拟电路近似表示,结合实例,PSpice仿真实验表明,小波函数的电路合成方法是有效、可靠的。     

模糊类比法在工程造价估算中的应用

工程造价的模糊估算方法是一种应用模糊数学的基本原理,对同一结构体系的拟建工程和已建工程结构方案的相似程序进行定量化对比和研究,从而快速地利用类似已建工程的造价资料估算拟建工程造价的方法。主要介绍该方法基本原理,并通过案例进行验证。     

Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a UK perspective

Aims/hypothesis:

Continuous subcutaneous insulin infusion (CSII) is an important treatment option for type 1 diabetes patients unable to achieve adequate glycemic control with multiple daily injections (MDI). Combining CSII with continuous glucose monitoring (CGM) in sensor-augmented pump therapy (SAP) with a low glucose-suspend (LGS) feature may further improve glycemic control and reduce the frequency of hypoglycemia. A cost-effectiveness analysis of SAP?+?LGS vs CSII plus self-monitoring of blood glucose (SMBG) was performed to determine the health economic benefits of SAP?+?LGS in type 1 diabetes patients using CSII in the UK.

Methods:

Cost-effectiveness analysis was performed using the CORE diabetes model. Treatment effects were sourced from the literature, where SAP?+?LGS was associated with a projected HbA_1c reduction of ?1.49% vs ?0.62% for CSII, and a reduced frequency of severe hypoglycemia. The time horizon was that of patient lifetimes; future costs and clinical outcomes were discounted at 3.5% and 1.5% per annum, respectively.

Results:

Projected outcomes showed that SAP?+?LGS was associated with higher mean quality-adjusted life expectancy (17.9 vs 14.9 quality-adjusted life years [QALYs], SAP?+?LGS vs CSII), and higher life expectancy (23.8 vs 21.9 years), but higher mean lifetime direct costs (GBP 125,559 vs GBP 88,991), leading to an incremental cost-effectiveness ratio (ICER) of GBP 12,233 per QALY gained for SAP?+?LGS vs CSII. Findings of the base-case analysis remained robust in sensitivity analyses.

Conclusions/interpretation:

For UK-based type 1 diabetes patients with poor glycemic control, the use of SAP?+?LGS is likely to be cost-effective compared with CSII plus SMBG.     

Cost-effectiveness of continuous subcutaneous insulin infusion in people with type 2 diabetes in the Netherlands

Aims: Up to 30% of insulin-treated type 2 diabetes patients are unable to achieve HbA1c targets despite optimization of insulin multiple daily injections (MDI). For these patients the use of continuous subcutaneous insulin infusion (CSII) represents a useful but under-utilized alternative. The aim of the present analysis was to examine the cost-effectiveness of initiating CSII in type 2 diabetes patients failing to achieve good glycemic control on MDI in the Netherlands. Methods: Long-term projections were made using the IMS CORE Diabetes Model. Clinical input data were sourced from the OpT2mise trial. The analysis was performed over a lifetime time horizon. The discount rates applied to future costs and clinical outcomes were 4% and 1.5% per annum, respectively. Results: CSII was associated with improved quality-adjusted life expectancy compared with MDI (9.38 quality-adjusted life years [QALYs] vs 8.95 QALYs, respectively). The breakdown of costs indicated that ～50% of costs were attributable to diabetes-related complications. Higher acquisition costs of CSII vs MDI were partially offset by the reduction in complications. The ICER was estimated at EUR 62,895 per QALY gained and EUR 60,474 per QALY gained when indirect costs were included. Conclusions: In the Netherlands, CSII represents a cost-effective option in patients with type 2 diabetes who continue to have poorly-controlled HbA1c despite optimization of MDI. Since the ICER falls below the willingness-to-pay threshold of EUR 80,000 per QALY gained, CSII is likely to represent good-value for money in the treatment of poorly-controlled T2D patients compared with MDI.     

汽车检测线模拟量的检测方法

本文重点研究轴重、制动等汽车检测线模拟量测试方法及数据处理。